Doctors are adding common blood pressure medications — drugs like hydralazine, losartan, and propranolol — to cancer treatment protocols because emerging research shows these medications can slow tumor growth, improve chemotherapy delivery, and significantly boost survival rates. This is not speculative. A Harvard-affiliated trial found that adding losartan to standard chemotherapy for locally advanced pancreatic cancer allowed complete tumor removal in 61 percent of participants. A 2026 Kaiser Permanente study of 1,332 women with metastatic breast cancer found that using multiple blood pressure drug classes was linked to a 38 percent reduction in all-cause mortality.
The science behind this repurposing is surprisingly straightforward. Blood pressure drugs target biological pathways — oxygen sensing, angiotensin signaling, stress hormones — that tumors exploit to grow, evade treatment, and resist the immune system. By blocking those pathways, these inexpensive, well-studied medications can make existing cancer therapies work better. For patients and caregivers already managing hypertension alongside a cancer diagnosis, this research carries particular weight. This article covers the specific drugs showing the most promise, the cancers they target, the clinical evidence behind each one, and the important limitations that patients should understand before assuming any blood pressure pill doubles as cancer treatment.
Table of Contents
- How Do Blood Pressure Drugs Actually Slow Cancer Growth?
- Losartan’s Expanding Role From Pancreatic Cancer to Leukemia
- Beta-Blockers and the Stress-Cancer Connection
- Blood Pressure Management and Breast Cancer Survival — What the Numbers Show
- The Limitations Patients and Caregivers Need to Understand
- Why This Matters for Dementia and Brain Health
- Where This Research Is Headed
- Conclusion
- Frequently Asked Questions
How Do Blood Pressure Drugs Actually Slow Cancer Growth?
The connection between blood pressure regulation and tumor biology runs deeper than most people realize. Tumors do not grow in isolation. They hijack the body’s vascular system, hormonal signaling, and oxygen-sensing machinery to feed themselves and dodge treatment. Blood pressure drugs, by design, target these same systems. Hydralazine, one of the oldest blood pressure medications still in clinical use, was recently found by University of Pennsylvania researchers to directly inhibit an enzyme called 2-aminoethanethiol dioxygenase, or ADO. This enzyme acts as a cellular oxygen sensor, and when hydralazine blocks it, glioblastoma cells enter a state called cellular senescence — they simply stop dividing. The findings, published in Science Advances in November 2025, showed that treating glioblastoma cells with hydralazine for just three consecutive days was enough to pause tumor growth.
What makes this mechanism particularly interesting is what it does not do. Unlike conventional chemotherapy, which kills rapidly dividing cells and often triggers inflammation and resistance, hydralazine halts division without provoking the inflammatory cascade that can make tumors more aggressive over time. For brain cancer patients and their families, this distinction matters. Glioblastoma is notoriously resistant to standard treatment, and any approach that sidesteps the usual resistance pathways deserves attention. However, there is a critical limitation. The hydralazine research has only been conducted in cell cultures so far — not in animals, and certainly not in human patients. The drug also does not easily cross the blood-brain barrier in therapeutic concentrations, which is why the Penn team’s next step involves designing more targeted ADO inhibitors. Promising cell-level results do not always translate to clinical benefit, and patients should not begin taking hydralazine for cancer based on preclinical data alone.
Losartan’s Expanding Role From Pancreatic Cancer to Leukemia
Losartan, a widely prescribed angiotensin receptor blocker, has the most robust clinical evidence of any blood pressure drug being repurposed for cancer. The landmark trial at Massachusetts General Hospital and Harvard added losartan to FOLFIRINOX chemotherapy plus radiation for patients with locally advanced pancreatic cancer — a diagnosis with notoriously poor outcomes. The results were striking. Sixty-one percent of participants were able to undergo complete surgical tumor removal, a rate far exceeding historical expectations for this stage of disease. Survival improved significantly as well. The mechanism is mechanical as much as chemical.
Tumors create a dense, compressed microenvironment that physically blocks chemotherapy drugs from reaching cancer cells and reduces the oxygen supply that radiation needs to work effectively. Losartan targets the angiotensin signaling pathway that maintains this compression, essentially loosening the tumor’s grip on its own blood supply and making it vulnerable to treatments that were already being administered. This same logic extends to other cancers. In mouse studies of acute myeloid leukemia, losartan enhanced chemotherapy efficacy by approximately 50 percent and improved heart function by roughly 30 percent — an important secondary benefit given that many chemotherapy agents are cardiotoxic. Research from the University of Notre Dame has also shown that losartan can reduce immunotherapy-induced edema in brain cancer while improving the structure of tumor blood vessels and enhancing the function of tumor-fighting immune cells. For anyone worried about whether ARBs themselves might contribute to cancer risk, an FDA-reviewed meta-analysis of 31 trials covering approximately 156,000 patients confirmed that angiotensin receptor blockers like losartan do not increase cancer risk. That safety profile makes losartan a particularly appealing candidate for combination therapy, though it is worth noting that not every cancer type or stage will benefit equally, and individual patient factors like kidney function and blood pressure levels must be weighed.
Beta-Blockers and the Stress-Cancer Connection
The case for beta-blockers in cancer treatment rests on a different biological pathway: the stress response. Adrenaline and noradrenaline — the hormones beta-blockers are designed to suppress — do more than raise heart rate and blood pressure. They also promote tumor angiogenesis, suppress immune surveillance, and facilitate metastasis. Propranolol, a nonselective beta-blocker prescribed since the 1960s, has drawn the most attention. A 2025 meta-analysis published in PMC found that beta-blockers were associated with longer progression-free survival across multiple cancer types. A separate systematic review of 31 studies, published in the Journal of Cancer Research and Clinical Oncology in 2025, concluded that propranolol may improve cancer outcomes especially when administered perioperatively — during the surgical window when the body’s stress response peaks and circulating tumor cells are most vulnerable.
Active Phase II clinical trials are currently investigating propranolol for bladder cancer, gastric cancer, esophageal cancer, and metastatic triple-negative breast cancer in combination with the immunotherapy drug pembrolizumab. The triple-negative breast cancer trial is particularly significant because this subtype has the fewest targeted treatment options and the worst prognosis among breast cancers. Adding a cheap, well-tolerated beta-blocker to immunotherapy could represent a meaningful advance if results hold. A 2026 study published in Pharmacology Research and Perspectives introduced a twist, however. Researchers comparing the molecular properties of various beta-blockers found that carvedilol may actually have more optimal anti-cancer properties than propranolol. Carvedilol’s additional alpha-blocking activity and antioxidant effects could make it a stronger candidate for prospective clinical trials. This is a reminder that “beta-blockers and cancer” is not a monolithic story — the specific drug, dose, timing, and cancer type all matter, and what works for one scenario may not apply to another.
Blood Pressure Management and Breast Cancer Survival — What the Numbers Show
For women already living with both hypertension and metastatic breast cancer, the practical implications of a 2026 Kaiser Permanente Southern California study are hard to ignore. Researchers led by Reina Haque, PhD, MPH, followed 1,332 women diagnosed with metastatic breast cancer between 2008 and 2020. The core finding was that women using multiple classes of blood pressure medications — polytherapy — had a 38 percent reduction in all-cause mortality compared to those on a single drug. Even more striking, women who consistently adhered to their blood pressure medications saw their mortality risk drop by 58 percent. This study, published in Cancer Medicine in February 2026, also highlighted a disparity that deserves attention. Nearly half of the women with metastatic breast cancer had hypertension at the time of their cancer diagnosis, with higher rates among Black and Hispanic patients.
These are the same populations that already face disparities in cancer treatment access and outcomes. The implication is that something as basic as managing blood pressure — which many patients and even some oncologists deprioritize once a terminal cancer diagnosis is made — could meaningfully extend survival. The comparison between polytherapy and monotherapy is especially practical. It suggests that aggressive, multi-drug blood pressure management is not just a cardiovascular concern for cancer patients but may actively support their cancer outcomes. This does not mean patients should request additional blood pressure medications solely for anti-cancer benefit. But it does mean that discontinuing or deprioritizing hypertension treatment after a cancer diagnosis — which happens more often than clinicians admit — could be doing real harm.
The Limitations Patients and Caregivers Need to Understand
The enthusiasm around repurposing blood pressure drugs for cancer treatment is warranted, but it comes with caveats that get lost in headline-driven reporting. First, the strongest results — like the hydralazine findings — come from preclinical work in cell cultures. Cell cultures are not patients. Drugs that halt cancer in a petri dish fail in human trials more often than they succeed. The leap from cell-level activity to a drug that works in a living body, crosses the blood-brain barrier, reaches therapeutic concentrations at the tumor site, and does so without unacceptable side effects is enormous. Second, even the more advanced clinical evidence, such as the losartan pancreatic cancer trial, applies to specific cancer types and stages. Locally advanced pancreatic cancer is not the same disease as metastatic pancreatic cancer, and results from one do not automatically transfer to the other.
Similarly, the Kaiser Permanente breast cancer findings are observational. The 38 percent mortality reduction associated with polytherapy could reflect other health behaviors correlated with taking multiple medications as prescribed, not a direct causal effect of the drugs themselves. Randomized controlled trials are needed to establish causation. Third, blood pressure drugs lower blood pressure. Patients undergoing cancer treatment frequently experience hypotension from chemotherapy, dehydration, or the disease itself. Adding a blood pressure-lowering drug to an already fragile hemodynamic state requires careful monitoring. No patient should begin taking losartan, propranolol, or hydralazine for possible anti-cancer benefit without explicit guidance from their oncology team. Self-prescribing based on research headlines is not just premature — it is dangerous.
Why This Matters for Dementia and Brain Health
The intersection of blood pressure management, cancer treatment, and brain health is tighter than it appears. Glioblastoma is the most common and aggressive primary brain tumor in adults, and any treatment advance — even preclinical — carries significance for the brain health community. Beyond glioblastoma, the losartan research showing reduced immunotherapy-induced brain edema and improved immune cell function in brain tumors has direct relevance for patients dealing with both cognitive decline and brain cancer, conditions that unfortunately co-occur in older adults.
There is also a broader connection. Poorly managed hypertension is one of the strongest modifiable risk factors for vascular dementia and Alzheimer’s disease. If the Kaiser Permanente findings hold — that aggressive, consistent blood pressure management improves cancer survival — they reinforce what the dementia research community has said for years: taking blood pressure medication faithfully is one of the single most impactful things older adults can do for their long-term health, whether the threat is cancer, stroke, or cognitive decline.
Where This Research Is Headed
The next few years will likely determine which of these blood pressure drugs transitions from “promising repurposing candidate” to standard-of-care addition. Propranolol’s Phase II trials for bladder, gastric, esophageal, and triple-negative breast cancers should begin reporting results, and the comparison between propranolol and carvedilol could reshape which beta-blocker clinicians favor. The Penn team’s effort to develop ADO inhibitors that cross the blood-brain barrier more effectively than hydralazine will be a bellwether for whether the senescence approach works in living patients, not just cells.
What makes this field particularly compelling is the economics. Hydralazine, losartan, and propranolol are all generic medications that cost pennies per dose. If even one of them proves to meaningfully improve cancer outcomes in randomized trials, it would represent one of the most cost-effective advances in oncology in decades — accessible to patients worldwide, not just those who can afford novel targeted therapies. For now, the evidence says: do not stop your blood pressure medications during cancer treatment, talk to your oncologist about whether any of these drugs might complement your regimen, and watch this space closely.
Conclusion
The repurposing of blood pressure drugs for cancer treatment is grounded in legitimate science, not wishful thinking. Hydralazine halts glioblastoma cell division by targeting oxygen-sensing enzymes. Losartan loosens the tumor microenvironment to let chemotherapy and radiation do their jobs, with clinical trial data showing 61 percent surgical eligibility in pancreatic cancer patients. Beta-blockers like propranolol dampen the stress hormones that help tumors spread, with active trials underway across multiple cancer types. And consistent, multi-drug blood pressure management is associated with meaningfully better survival in women with metastatic breast cancer.
None of this means blood pressure pills are cancer cures. The evidence ranges from preclinical cell studies to observational data to a handful of clinical trials, and each drug-cancer combination needs its own rigorous validation. But for patients and caregivers navigating a cancer diagnosis alongside hypertension — which describes nearly half of older cancer patients — the message is clear: blood pressure management is not a side issue. It may be an active part of treatment. Talk to your medical team about what these findings mean for your specific situation, and do not let a cancer diagnosis become a reason to neglect cardiovascular care.
Frequently Asked Questions
Can I take blood pressure medication specifically to prevent cancer?
There is no evidence that taking blood pressure drugs prevents cancer in people without hypertension. The research focuses on patients who already have cancer and are using these drugs alongside standard treatment. An FDA meta-analysis of 156,000 patients confirmed ARBs do not increase cancer risk, but that is a safety finding, not a prevention claim.
Should I ask my oncologist to add losartan to my chemotherapy?
You should discuss it, but the decision depends entirely on your cancer type, stage, current blood pressure, kidney function, and existing medications. The strongest evidence for losartan is in locally advanced pancreatic cancer. It has not been proven for all cancers, and adding it without medical supervision risks dangerous drops in blood pressure during treatment.
Are beta-blockers better than ACE inhibitors or ARBs for cancer patients?
The research suggests different drug classes may benefit different cancers through different mechanisms. Beta-blockers like propranolol target stress hormones that promote metastasis, while ARBs like losartan address the physical tumor microenvironment. The 2026 Kaiser Permanente study found that using multiple classes together was associated with the best outcomes, suggesting these effects may be complementary rather than competitive.
Is the hydralazine brain cancer research ready for clinical use?
No. The University of Pennsylvania findings are from cell culture experiments only. Hydralazine has not been tested against glioblastoma in animals or humans, and it does not cross the blood-brain barrier effectively enough for brain tumor treatment at standard doses. The researchers are developing more targeted compounds as a next step.
Does this research apply to people with dementia who also have cancer?
The brain health implications are real but indirect. Losartan research shows benefits for brain tumor treatment specifically, and consistent blood pressure management protects cognitive function independently of cancer. For older adults managing both conditions, the key takeaway is that blood pressure medications should not be deprioritized after a cancer diagnosis.
Are there risks to combining blood pressure drugs with cancer treatment?
Yes. Cancer patients often experience low blood pressure from chemotherapy, nausea, dehydration, or the disease itself. Adding blood pressure-lowering drugs can worsen hypotension, causing dizziness, falls, or organ damage. Any addition must be monitored by the treating oncology and cardiology teams together.
